• Services
    • Overview
    • Autoantibody Biomarker Profiling
    • Oncology Drug Screening
    • Systems Serology
    • Vaccine Development
    • Custom Protein Arrays
  • Products
    • Overview
    • i-Ome Protein Array Kit
    • Seromax Blood Collection Kit
  • Applications
        • Disease Area
          • Autoimmune Disease
          • Immuno-oncology
          • Neurological Disease
          • Infectious Disease
        • Application Area
          • Biomarker Discovery
          • Patient Stratification
          • Response & Adverse Event Prediction
          • Diagnostics & CDx Development
  • Technology
    • Overview
    • KREX Protein Folding Technology
    • ORVAR Autoantigen Discovery Platform
    • The Value of Autoantibodies
    • Bioinformatics for Autoantibodies
  • Resources
    • Videos
    • Publications
    • Product Information
    • White Papers & Case Studies
    • Protein List
    • FAQ
  • About
    • Company Overview
      • Patents
    • Meet Our Team
    • News & Events
  • Menu Menu
  • Join Our Team
  • Contact

News & Events

Keep up to date on Sengenics news and events

Press Releases

Sengenics Launches ImmuSAFE COVID+, the World’s First High-Throughput, Multi-Antigen COVID-19 Biochip Test

June 23, 2020
Learn More →
Press Releases

Sengenics Announces New Research Collaboration with GSK Focusing on Immunology

June 18, 2020
Learn More →
Press Releases

Sengenics Successfully Produces Functional COVID-19 Antigens and Makes Them Available for Research and Vaccine Development

March 13, 2020
Learn More →
Press Releases

Sengenics, a Leading Precision Medicine Focused Company, to Present at the Annual BIO CEO and Investor Conference

January 28, 2020
Learn More →
Press Releases

Sengenics, a Leading Commercial Stage Precision Medicine Focused Company, which Enables Pharma Companies to Identify Drug Responders, to Present at Biotech Showcase™ 2020

December 18, 2019
Learn More →
Press Releases

Renal Cancer Research by Sengenics and the University of Leeds Awarded Early Detection Primer Grant Funding from Cancer Research UK

November 26, 2019
Learn More →
Press Releases

Sengenics Partners with the Foundation for the National Institutes of Health Biomarkers Consortium

July 11, 2019
Learn More →
Press Releases

Sengenics Partners with Olivia Newton-John Cancer Research Institute to Enhance Safety of Cancer Immunotherapy Drugs

October 5, 2018
Learn More →
  • ‹
  • 1
  • 2
  • 3
Loading...

  • Services
  • Products
  • Applications
  • Technology
  • Resources
  • About

Sengenics is a precision medicine company working to improve patient outcomes through physiologically relevant, data-guided decision making. Our solutions enable the discovery and validation of autoantibody biomarker signatures for patient stratification, therapeutic response prediction and development of companion diagnostics.

Copyright 2008 – 2022 Sengenics All rights reserved. Sengenics Corporation LLC. Registered in Delaware, USA no. 5739583 | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D

Terms & Conditions | Terms of Use | Privacy Statement | Cookie Policy | Code of Conduct | Whistleblowing Policy

Design and development by RainCastle Communications.

This site uses cookies. By continuing to use this site, you accept our use of cookies. Learn more about our Privacy Statement and Cookie Policy here.

I Accept

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visit to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Other cookies

The following cookies are also needed - You can choose if you want to allow them:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Accept settingsHide notification only